nmCRPC

Zoledronic Acid Benefited Those With Bone Mets Regardless of HSPC/CRPC Status
Zoledronic acid (ZA) did not improve survival outcomes in patients with different prostate cancer statuses outside of metastatic castration-resistant disease, including those with hormone-sensitive disease, according to the results of a recent meta-analysis published in PLoS One. “ZA is the most potent bisphosphonates and is currently recommended for the management of bone metastasis in various solid tumors. It functions as an adjunctive treatment and bone-targeted therapy for supportive care with metastatic castration-resistant prostate cancer,” study researchers explained. ...
Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Trending

Advertisement